SCHEMBL24019658

SCHEMBL24019658

Cc1cccc2c1C(C(C)C)C(=O)N2

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TP53 P04637 4/20 0.43
MAPT P10636 3/20 0.43
CREBBP Q92793 5/20 0.41
BRD4 O60885 2/20 0.40
PBRM1 Q86U86 1/20 0.39
BRPF1 P55201 1/20 0.38
MAOB P27338 1/20 0.38
PARP1 P09874 1/20 0.35
DDB1 Q16531 1/20 0.35
CRBN Q96SW2 1/20 0.35
POLB P06746 1/20 0.34
LMNA P02545 1/20 0.34
THRB P10828 1/20 0.34
DAO P14920 1/20 0.33
TNKS O95271 1/20 0.33
TNKS2 Q9H2K2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24029081 1.00 TP53 (0.43) TP53MAPTCREBBPBRD4PBRM1
SCHEMBL24019656 0.82 HTR5A (0.45) TP53MAPTCREBBPPBRM1BRPF1
SCHEMBL24740178 0.82 HTR5A (0.45) TP53MAPTCREBBPPBRM1BRPF1
SCHEMBL5733757 0.81 CYP1A2 (0.39) TP53MAPTCREBBPBRD4BRPF1
SCHEMBL23835846 0.81 MAOB (0.42) TP53MAPTCREBBPPBRM1BRPF1
SCHEMBL23836112 0.81 MAOB (0.42) TP53MAPTCREBBPPBRM1BRPF1
SCHEMBL24112853 0.79 CREBBP (0.47) CREBBPBRD4PBRM1BRPF1PARP1
SCHEMBL24112741 0.79 CREBBP (0.47) CREBBPBRD4PBRM1BRPF1PARP1
SCHEMBL5732840 0.78 CREBBP (0.40) TP53MAPTCREBBPMAOBDDB1
SCHEMBL20850825 0.76 CREBBP (0.41) TP53MAPTCREBBPBRD4PBRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 US disclosed
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 US disclosed
US-20220402896-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2022-12-22 US disclosed
US-11524940-B1 Inhibitors of cysteine proteases and methods of use thereof Pardes Biosciences, Inc. (US) 2022-12-13 US disclosed
US-20220162194-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2022-05-26 US disclosed
US-11174231-B1 Inhibitors of cysteine proteases and methods of use thereof Pardes Biosciences, Inc. (US) 2021-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220162194-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTSV, CTRL, CTSL TP53 527/4885MAPT 2276/4885CREBBP 2433/4885
US-20220402896-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTSV, CTRL, CTSL TP53 527/4885MAPT 2276/4885CREBBP 2433/4885
US-11174231-B1 Inhibitors of cysteine proteases and methods of use thereof CTRL, CTSV, CTSL TP53 237/4885MAPT 1905/4885CREBBP 2077/4885
US-11524940-B1 Inhibitors of cysteine proteases and methods of use thereof CTRL, CTSV, CTSL TP53 237/4885MAPT 1905/4885CREBBP 2077/4885
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTRL, CTSL, CTSV TP53 524/4885MAPT 2314/4885CREBBP 2437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.